AstraZeneca Announces FDA Complete Response Letter Regarding NDA for PT010 in COPD

October 1, 2019 -- AstraZeneca today announced that the US Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for PT010 (budesonide/glycopyrronium/formoterol fumarate), an inhaled...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials